Myeloma kidney, also known as light chain cast nephropathy, is the most common cause of kidney impairment in patients with multiple myeloma. Although it is commonly referred to as myeloma kidney or myeloma cast nephropathy this entity can also occur in patients with Waldenstrom macroglobulinemia and less commonly in CLL. Renal risk from myeloma is very dependent on the burden of circulating monoclonal FLC rather than the amount of M protein spike. Treatment of myeloma with bortezemib is most effective at reducing light chain burden. However, novel therapies with plasmapheresis and high cut-off hemodialysis are currently being studied.
See the Current Standings! | For more on NephMadness 2015 | #NephMadness or #OncoRegion on Twitter Nephron-Sparing Surgery versus Nephrectomy for Renal Cancer Winner: Nephron-Sparing Surgery 6-1 split Taking the kidney out and curing the cancer is a [read more...]
Jeffrey Zonder, hematologist at Karmanos Cancer Institute in Detroit Michigan and author of the Amyloid Planet Blog breaks down amyloid versus myeloma in the onconephrology region. He is a Duke graduate so it is okay to hate him. As you consider [read more...]
Submit your picks! | For more on NephMadness 2015 | #NephMadness or #OncoRegion on Twitter Onconephrology is wide subject ranging from renal cancers, to side effects from chemo- and radiotherapy to renal paraneoplastic processes like amyloidosis. [read more...]